HCA
CBAY

Harbor Capital Advisors’s Cymabay Therapeutics CBAY Stock Holding History

Harbor Capital Advisors’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-4,701
Closed -$51.5K – 667
2023
Q2 		$51.5K Buy
+4,701
New +$43.8K 0.01% 490

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Harbor Capital Advisors's CBAY Position: Q3 2023 in Review

Harbor Capital Advisors sold out of Cymabay Therapeutics (CBAY) in Q3 2023, closing a stake of 4,701 shares — an estimated $51.5K sold.

Harbor Capital Advisors first reported a position in CBAY in Q2 2023 and held it in 1 quarter. The position peaked at $51.5K in Q2 2023. 189 funds tracked by Wall St. Rank hold CBAY as of Q3 2023.

  • Harbor Capital Advisors reported no remaining Cymabay Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Harbor Capital Advisors sold 4,701 Cymabay Therapeutics shares in Q3 2023, an estimated $51.5K.
  • Harbor Capital Advisors first reported a position in Cymabay Therapeutics in Q2 2023 and held it in 1 quarter.
  • Harbor Capital Advisors's Cymabay Therapeutics position peaked at $51.5K in Q2 2023.
  • 189 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q3 2023.

Based on Harbor Capital Advisors's 13F filing for Q3 2023, filed 20 Oct 2023.